New pill aims to tame stubborn high blood pressure
NCT ID NCT07489612
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new daily pill called QLS1410 in 260 adults whose high blood pressure remains high despite taking two or more medications. Participants will receive either QLS1410 or a placebo for 12 weeks. The main goal is to see if QLS1410 can lower systolic blood pressure more than placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QLS1410 tablet
What this could lead to
If it works, this could provide a new daily pill option for people whose high blood pressure is not controlled by current medications.
What could go wrong
This is an early Phase 2 trial with only 260 participants, so results may not apply to everyone. The drug is still experimental and may not lower blood pressure better than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT RESISTANT HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Qilu Hospital of Shandong University
Jinan, China